Company Overview of Regen BioPharma Inc.
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It intends to provide various products, including HemaXellerate I, a cellular therapy designed to heal damaged bone marrows; HemaXellerate II, a donor endothelial cell based therapeutic product; dCellVax, a gene silenced dendritic cell immunotherapy for the treatment of breast cancer; and NR2F6, a nuclear receptor cell line. The company was founded in 2012 and is based in La Mesa, California. Regen BioPharma, Inc. is a subsidiary of Bio-Matrix Scientific Group, Inc.
4700 Spring Street
La Mesa, CA 91942
Founded in 2012
Key Executives for Regen BioPharma Inc.
Chairman, Chief Executive Officer, Principal Accounting Officer, Treasurer, Secretary, Chairman of Bio-Matrix Scientific Group and Chief Executive Officer of Bio-Matrix Scientific Group
Total Annual Compensation: $210.0K
Chief Financial Officer and Director
Total Annual Compensation: $101.3K
Senior Research Consultant
Total Annual Compensation: $120.0K
Compensation as of Fiscal Year 2015.
Regen BioPharma Inc. Key Developments
Regen BioPharma Inc. Announces the Completion of Experiments Demonstrating Immunological Effects of Novel NR2F6 Small Molecule Modulators
Sep 20 16
Regen BioPharma Inc. announced completion of experiments demonstrating immunological effects of its novel NR2F6 small molecule modulators. These experiments were conducted in collaboration with Dr. Xiaojing Ma, Professor of Microbiology and Immunology at Weill Cornell Medical College. The experiments revealed that administration of Regen's proprietary compounds RG-NA01, RG-NI01 and RG-NI02 prevented cells of the immune system from producing the inflammatory factors interleukin-2, interferon-gamma, tumor necrosis factor-alpha and, importantly, interleukin-17a. These factors are critically involved in the immune response found in autoimmune diseases such as rheumatoid arthritis and psoriasis. The company is currently developing small molecule drugs that target NR2F6 and either inhibit production of these factors or, in other cases, stimulate their production. The goal is to have a series of compounds that can modulate the immune system up or down. Regen has recently filed a composition of matter patent application covering these novel NR2F6 small molecule modulators. NR2F6 is a molecular switch which controls genes associated with the immune response.
Regen BioPharma Inc. Announces Small Molecule Drug Screening Program Uncovers Activators of NR2F6
Jun 14 16
Regen BioPharma Inc. announced identification of small molecules that activate the company's newly identified immune checkpoint NR2F6. This is the first of a series of steps in developing small molecules which the company plans to use as a basis for creating an oral drug that may have potent anti-inflammatory properties. Previously, the company reported that suppressing NR2F6 leads to immune cell activation, including production of the immune-stimulatory cytokines IL-18, IL-17 and IL-2. Thus, activating NR2F6 will likely lead to immune suppression. Given the difficult nature of the NR2F6 target, Regen is excited that using very stringent parameters, the company has been able to identify molecules that not only bind and activate it but also have structural properties making them excellent starting points for drug development. Regen is also optimistic the company will identify inhibitors of NR2F6 in the coming months." NR2F6 is a molecular switch known as a "orphan nuclear receptor" which controls genes associated with the immune response. Regen has filed numerous patent applications covering means of manipulating NR2F6 in oncology and immunology.
Regen Biopharma Inc. Receives Preliminary Clinical Data from Pan Am Cancer Center
May 3 16
Regen BioPharma Inc. announced that the Pan Am Cancer Treatment Center in Tijuana, Mexico, which has a non-exclusive license to test HemaXellerate in a first-in-human proof of concept study, presented interim clinical data on their first 5 patients. Beginning in March 2016, 5 patients with chemotherapy-induced bone marrow suppression were treated with HemaXellerate and initial 1 month follow up data were provided. The primary endpoint of the study is safety and the secondary endpoint is effectiveness. Regarding safety, none of the 5 patients had any adverse events. In other words, all of the patients tolerated HemaXellerate with no side-effects. Effectiveness was measured by taking blood tests of the patients 1 month post-HemaXellerate treatment and measuring the levels of blood cells, particularly immune cells, circulating in their blood. At 1 month post-HemaXellerate treatment, 2 patients (40%) had a dramatic increase in their circulating white blood cells to levels even above the normal range and 2 other patients had their white blood cells return to the normal range.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 1, 2016
March 22, 2016
February 22, 2016